Tìm theo
Agomelatine
Các tên gọi khác (1) :
  • Valdoxan
antidepressive agents
Thuốc Gốc
Small Molecule
CAS: 138112-76-2
ATC: N06AX22
CTHH: C15H17NO2
PTK: 243.301
Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C15H17NO2
Phân tử khối
243.301
Monoisotopic mass
243.125928793
InChI
InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
InChI Key
InChIKey=YJYPHIXNFHFHND-UHFFFAOYSA-N
IUPAC Name
N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
Traditional IUPAC Name
agomelatine
SMILES
COC1=CC2=C(C=CC=C2CCNC(C)=O)C=C1
Độ hòa tan
~0.5 mg/ml in 1:1 EtOH:PBS (pH 7.2); ~30 mg/ml in EtOH, DMF & DMSO
logP
2.04
logS
-4.5
pKa (strongest acidic)
15.96
pKa (Strongest Basic)
-0.94
PSA
38.33 Å2
Refractivity
71.64 m3·mol-1
Polarizability
27.18 Å3
Rotatable Bond Count
4
H Bond Acceptor Count
2
H Bond Donor Count
1
Physiological Charge
0
Number of Rings
2
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Agomelatine resynchronises circadian rhythms in animal models of delayed sleep phase syndrome and other circadian rhythm disruptions. It increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin. Agomelatine has shown an antidepressant-like effect in animal models of depression (learned helplessness test, despair test, chronic mild stress) as well as in models with circadian rhythm desynchronisation and in models related to stress and anxiety. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset. Controlled studies in humans have shown that agomelatine is as effective as the SSRI antidepressants paroxetine and sertraline in the treatment of major depression
Cơ Chế Tác Dụng : Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was discovered and developed by the European pharmaceutical company Servier Laboratories Ltd. Servier continue to develop the drug and conduct phase III trials in the European Union. In 2005 Servier submitted Agomelatine to the European Medicines Agency (EMEA). On 27 July 2006 the Committee for Medical Products for Human Use (CHMP) of the EMEA recommended a refusal of the marketing authorisation of Valdoxan/Thymanax. The major concern was that efficacy had not been sufficiently shown. In 2006 Servier sold the rights to develop Agomelatine in the US to Novartis. The development for the US market was discontinued in October 2011. It is currently sold in Australia under the Valdoxan trade name. The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors.
Dược Động Học :
▧ Absorption :
Bioavailability is less than 5%.
▧ Protein binding :
> 95%
▧ Metabolism :
Hepatic (90% CYP1A2 and 10% CYP2C9).
▧ Half Life :
<2 hours
Chỉ Định : Agomelatine is indicated for the treatment of major depressive episodes in adults.
Liều Lượng & Cách Dùng : Tablet - Oral
Dữ Kiện Thương Mại
Nhà Sản Xuất
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB06594
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=82148
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D02578
ChemSpider
http://www.chemspider.com/Chemical-Structure.74141.html
BindingDB
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50035179
PharmGKB
http://www.pharmgkb.org/drug/PA165958363
Wikipedia
http://en.wikipedia.org/wiki/Agomelatine
... loading
... loading